CA3069143A1 - Compositions and methods for treating or preventing endocrine fgf-linked diseases - Google Patents

Compositions and methods for treating or preventing endocrine fgf-linked diseases Download PDF

Info

Publication number
CA3069143A1
CA3069143A1 CA3069143A CA3069143A CA3069143A1 CA 3069143 A1 CA3069143 A1 CA 3069143A1 CA 3069143 A CA3069143 A CA 3069143A CA 3069143 A CA3069143 A CA 3069143A CA 3069143 A1 CA3069143 A1 CA 3069143A1
Authority
CA
Canada
Prior art keywords
construct
klotho
fgf21
antibody
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069143A
Other languages
English (en)
French (fr)
Inventor
Joseph Schlessinger
Sangwon Lee
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CA3069143A1 publication Critical patent/CA3069143A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
CA3069143A 2017-07-06 2018-07-05 Compositions and methods for treating or preventing endocrine fgf-linked diseases Pending CA3069143A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529215P 2017-07-06 2017-07-06
US62/529,215 2017-07-06
PCT/US2018/040932 WO2019010314A1 (en) 2017-07-06 2018-07-05 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ENDOCRINE FGF-RELATED DISEASES

Publications (1)

Publication Number Publication Date
CA3069143A1 true CA3069143A1 (en) 2019-01-10

Family

ID=64950347

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069143A Pending CA3069143A1 (en) 2017-07-06 2018-07-05 Compositions and methods for treating or preventing endocrine fgf-linked diseases

Country Status (7)

Country Link
US (2) US11365228B2 (enExample)
EP (1) EP3649157A4 (enExample)
JP (2) JP7316946B2 (enExample)
CN (1) CN110997726B (enExample)
AU (1) AU2018297285A1 (enExample)
CA (1) CA3069143A1 (enExample)
WO (1) WO2019010314A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN111420030B (zh) * 2020-05-12 2021-01-29 江南大学 Fgf21在制备用于治疗结直肠癌药物中的应用
CN115667925A (zh) * 2020-05-15 2023-01-31 阿雷克森制药公司 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
CN112851791B (zh) 2021-03-12 2021-10-22 江南大学 一种新型抗代谢紊乱的fgf类似物及其应用
CN113105561B (zh) * 2021-04-30 2021-12-03 江南大学 一种双靶点融合蛋白的制备方法和应用
EP4777130A1 (en) * 2023-09-11 2026-07-22 Yale University Constructs for modulating fgf21/fgfr/beta-klotho signaling pathway and treating diseases and disorders, and methods thereof
CN118852466B (zh) * 2024-08-08 2025-03-28 郑州大学第三附属医院(河南省妇幼保健院) Klotho修饰的CAR-T结构及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TW201446265A (zh) 2007-04-02 2014-12-16 建南德克公司 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ調節劑之用途
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
SG193860A1 (en) 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
WO2011158655A1 (ja) 2010-06-15 2011-12-22 国立大学法人広島大学 石灰化組織における可溶化Klotho、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途
AU2012254160A1 (en) * 2011-05-10 2013-11-21 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of FGFR1 and beta-Klotho
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
WO2013131091A1 (en) * 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
US9464126B2 (en) * 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9400677B2 (en) 2013-01-02 2016-07-26 Apple Inc. Adaptive handling of priority inversions using transactions
WO2015138278A1 (en) 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CN106456714A (zh) 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
CA2969307A1 (en) 2014-12-04 2016-06-09 Novartis Ag Methods and compositions using klotho variant polypeptides
WO2016204884A1 (en) 2015-06-18 2016-12-22 Albert Einstein College Of Medicine, Inc. Fgf receptor ligands for treating diabetes and obesity
WO2017079768A1 (en) * 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
US20190142963A1 (en) * 2016-04-15 2019-05-16 Richard D. DiMarchi Fgf21 c-terminal peptide optimization
EP3463427A4 (en) 2016-05-25 2020-03-11 Board of Regents, The University of Texas System METHOD AND COMPOSITIONS FOR TREATING SECRETORIC DISEASES
WO2018026899A1 (en) 2016-08-03 2018-02-08 Joslin Diabetes Center, Inc. Methods and compositions for treating hypoglycemia

Also Published As

Publication number Publication date
WO2019010314A1 (en) 2019-01-10
CN110997726B (zh) 2024-10-29
US20200131257A1 (en) 2020-04-30
EP3649157A1 (en) 2020-05-13
JP7316946B2 (ja) 2023-07-28
US20240083961A1 (en) 2024-03-14
US11365228B2 (en) 2022-06-21
JP2023103455A (ja) 2023-07-26
US12534503B2 (en) 2026-01-27
EP3649157A4 (en) 2021-07-28
CN110997726A (zh) 2020-04-10
JP2020526503A (ja) 2020-08-31
AU2018297285A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US12534503B2 (en) Mutant fibroblast growth factor 21 (FGF21) polypeptides
JP6114326B2 (ja) 組織因子経路阻害因子に対する抗体
JP4584713B2 (ja) 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
KR20190082815A (ko) 중화 항-tl1a 단일 클론 항체
JP2019510739A (ja) Ｇｆｒａｌ受容体療法
BRPI1011404B1 (pt) Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
JP2016146844A (ja) 抗アクチビンａ抗体およびその使用
TW201722989A (zh) 抗il-2抗體及其組合物及用途
EP2732823A1 (en) Modulation of the TrpV : Vps10p-domain receptor system for the treatment of pain
UA120357C2 (uk) Виділене біспецифічне антитіло, що специфічно зв'язується з klb і fgfr1 та спосіб його застосування
KR20110028536A (ko) Ｆｇｆ-ｒ４ 수용체-특이적 길항제
JP2019521647A (ja) 成長分化因子１５に対する抗体およびそれらの使用
CN110520151B (zh) 胰高血糖素受体结合蛋白和其使用方法
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
US11548942B2 (en) Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody
EP4377343A2 (en) Compositions and methods for anti-pacap antibodies
CN115243763A (zh) 治疗进行性骨化性纤维发育不良
EP3491021B1 (en) Anti-canine platelet derived growth factor receptor alpha antibody
RU2820628C2 (ru) Белки, связывающие глюкагоновые рецепторы, и способы их применения
US20200331978A1 (en) Compositions and Methods for Treating or Preventing Endocrine FGF23-Linked Diseases
HK40111253A (en) Compositions and methods for anti-pacap antibodies
WO2025059130A1 (en) Constructs for modulating fgf21/fgfr/beta-klotho signaling pathway and treating diseases and disorders, and methods thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230627

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250402

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260609

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260609